Live
Lupin said that it has concluded the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS).
The acquisition was announced by Lupin on July 23, 2015.
Lupin has said in a statement that the acquisition enhances the company’s scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics.
Vinita Gupta, Lupin CEO said that “The GAVIS portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”
